Anti-amyloid antibodies market seen reaching $6.54 billion by 2030

The anti-amyloid antibodies market is projected to grow from $3.27 billion in 2025 to $6.54 billion by 2030, driven by Alzheimer’s disease demand, more disease-modifying therapies and advances in antibody engineering. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Anti-amyloid antibodies are aimed at amyloid-beta plaques linked to Alzheimer’s disease, giving the category direct exposure to one of the largest unmet needs in neurodegenerative care. - The market’s projected jump to $6.54 billion by 2030 signals sustained commercial momentum for therapies that try to slow disease progression, not just manage symptoms.

What happened: - The Business Research Company said the global anti-amyloid antibodies market was valued at $3.27 billion in 2025 and is projected to reach $3.75 billion in 2026. - The market report forecasts growth to $6.54 billion by 2030, implying a 14.9% compound annual growth rate from 2026 to 2030. - The company published the forecast in its Anti-Amyloid Antibodies Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The report includes a free sample and the full market report.

The details: - Anti-amyloid antibodies are monoclonal antibodies or immunotherapy agents designed to bind amyloid aggregates and help clear them from the brain. - The treatment approach targets amyloid-beta plaques that accumulate in the brain and are closely tied to Alzheimer’s disease. - The market’s recent growth is linked to rising Alzheimer’s cases, limited success from existing symptomatic treatments, increased research funding for the amyloid hypothesis, advances in monoclonal antibody technology and a larger elderly population. - The report expects future demand to be driven by more approvals for disease-modifying Alzheimer’s therapies, broader early biomarker screening, higher investment in neuroimmunology, wider use of personalized medicine and next-generation antibody engineering. - The report also flags AI-powered biomarker discovery, digital health monitoring tools, cloud-based clinical trial analysis and scalable monoclonal antibody biomanufacturing as key trends. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to grow the fastest over the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report says 2026 editions include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspot infographics, and updated technology and trend analysis.

Between the lines: - The forecast reflects a broader shift in Alzheimer’s care toward therapies that target disease biology earlier in the treatment path. - The emphasis on biomarker screening and precision medicine suggests the market may depend as much on diagnostics and care pathways as on the antibodies themselves. - The demographic backdrop remains central: the Alzheimer’s Association projected in March 2024 that the number of Americans 65 and older living with Alzheimer’s disease will rise to 13.8 million by 2060.

What's next: - The market’s near-term pace will likely track regulatory approvals, diagnostic adoption and investment in next-generation antibody platforms. - Regional growth may widen as healthcare access improves in Asia-Pacific and research spending expands in emerging markets. - The Business Research Company continues to market its broader research platform and market intelligence tools to customers tracking sector forecasts.